Moderna’s mRNA cancer vaccine shows promise in preliminary study

wsj

3 min read . Updated: 13 Dec 2022, 07:30 PM IST Peter Loftus, The Wall Street Journal

The companies said Tuesday the combination of Moderna’s personalized cancer vaccine and Merck’s Keytruda cancer immunotherapy reduced patients’ risk of relapse or death by about 44% (Reuters) — The companies said Tuesday the combination of Moderna’s personalized cancer vaccine and Merck’s Keytruda cancer immunotherapy reduced patients’ risk of relapse or death by about 44% (Reuters)

The shot combined with a Merck immunotherapy reduced the risk of relapse in people with skin cancer in a study, Moderna said

A customized Moderna Inc. vaccine combined with a Merck & Co. cancer drug helped ward off the recurrence of the skin cancer melanoma after surgery in patients in a mid-stage clinical trial, the companies said.